- 1,380studies on this subject, of 27,380 in the library
- 1,333peer-reviewed
- 1983–2026years published
- 40median usefulness score out of 100
These counts and lists are worked out from the library itself each time the page loads. A score rates how much weight a study can bear — its design, journal, evidence and recency — not whether its result is good news. How we score a study.
The 20 highest-scoring studies
- Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis
- The microbiota-gut-brain axis in mild cognitive impairment and Alzheimer's disease: a scoping review of human studies
- Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities
-
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease
In this 24-week phase 2 trial in mild Alzheimer's disease, the drug neflamapimod did not improve the main or secondary clinical measures compared with placebo. It did significantly lower spinal-fluid levels of total tau and p-tau 181, markers of nerve damage and tau disease. Combined with signals in people with the highest drug levels, the authors argue a longer, higher-dose study is warranted, so any clinical benefit remains unproven.
- Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts
- Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases
- Probiotic intervention benefits multiple neural behaviors in older adults with mild cognitive impairment
- The intestinal microbiota as an ally in the treatment of Alzheimer's disease
- Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study
- Gut microbiota, cognitive frailty and dementia in older individuals: a systematic review
- Serum IgG antibody levels to periodontal microbiota are associated with incident Alzheimer disease
-
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
In three cohorts, plasma eMTBR-tau243 was elevated at the mild cognitive impairment stage and increased further in dementia, and it was strongly associated with tau PET binding and cognitive performance, outperforming other plasma tau biomarkers. This is a blood biomarker for detecting and tracking tau tangles, not a treatment, cure or prevention.
- Structural progression of Alzheimer's disease over decades: the MRI staging scheme
- Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study
-
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis
Pooling 49 articles, this review found Alzheimer-type tau tangles (Braak stage ≥ III) in 66% of people with dementia with Lewy bodies and 52% with Parkinson's disease dementia at autopsy. In dementia with Lewy bodies, more tau was linked to fewer hallucinations, less parkinsonism, worse cognition before death and lower accuracy of diagnosis during life. The authors conclude tau is common in these dementias and may make dementia with Lewy bodies harder to diagnose correctly during life.
-
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study
In a phase 2a trial in people with Alzheimer's, the glutaminyl cyclase inhibitor PQ912 cut the target enzyme's activity, reaching an average target occupancy of > 90%, and was linked to a reduction in EEG theta power and better scores on one memory test. Serious adverse events were slightly more common than on placebo, though not significantly different. The authors see only early signals of efficacy and call for longer studies at lower doses.
- Gut Microbiome Alterations in Mild Cognitive Impairment: Findings from the ALBION Greek Cohort
-
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
This paper describes the amyloid hypothesis, which proposes that accumulation of amyloid beta-peptide in the brain is the primary influence driving Alzheimer's disease pathogenesis. According to the hypothesis, the rest of the disease process, including formation of neurofibrillary tangles containing tau protein, is proposed to result from an imbalance between amyloid beta production and clearance.
-
β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE
This study cloned and characterized BACE, an enzyme with the characteristics of beta-secretase, which cleaves amyloid precursor protein to produce amyloid beta peptide. It suggests that future development of BACE inhibitors may be beneficial for treating Alzheimer's disease, but no treatment was tested in people.
-
TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis
This study identified mutations in the TARDBP gene in people with amyotrophic lateral sclerosis (ALS), a motor neuron disorder, and found that mutant TDP-43 caused neural apoptosis in a chick embryo model. It does not test a treatment or cure for Alzheimer's disease.
See all 1,380 studies in Disease mechanisms, with filters →
Newest additions on this subject
- Aβ42 oligomers disrupt calcium homeostasis via Piezo1 and induce neurotoxicity in differentiated SH-SY5Y cells
- Neuronal Hyperactivity Induces Tau Phosphorylation Selectively in Excitatory Pyramidal Neurons Which Contributes to GluA2 Regulation
- Anti-GABA B receptor autoimmunity causes cognitive decline by presynaptic pathology
- SpineTool 2.0: A Deep Learning Platform with an Interactive User Interface for Dendritic Spine Segmentation and Morphological Analysis
- BNIP3L/NIX-mediated mitophagy limits Alzheimer’s disease pathology and preserves neuronal function
- Convergent Mitochondrial and Oxidative Stress Signatures in Spaceflight and Tauopathy: A Comparative Multi-Omics Reanalysis in Drosophila melanogaster
- The Alzheimer’s disease risk gene ABCA7 regulates microglial lysosomal and lipid homeostasis and promotes phagocytosis to maintain neuronal health
- LATS2 modulates synaptic organization and function by regulating actin dynamics
- Change in gut microbiome precedes symptomatic Alzheimer’s disease and is correlated with amyloid-beta accumulation in the brain
- Spatiotemporal transcriptomic dynamic across the auditory pathway from young to old age in 5xFAD Alzheimer disease mice
All 1,380 studies in Disease mechanisms, newest first →
What the library holds on this subject
By review status
| Status | Studies |
|---|---|
| Peer-reviewed | 1,333 |
| Preprint — not yet peer-reviewed | 46 |
| Retracted — do not rely on it | 1 |
By strength of evidence
| Rated in our summary | Studies |
|---|---|
| low | 1,241 |
| moderate | 72 |
| not rated | 39 |
| high | 28 |
Most frequent journals
| Journal | Studies |
|---|---|
| The Journal of neuroscience : the official journal of the Society for Neuroscience | 40 |
| Acta neuropathologica | 26 |
| Nature | 26 |
| Journal of neuropathology and experimental neurology | 25 |
| The Journal of biological chemistry | 25 |
| bioRxiv | 25 |
| Journal of Alzheimer's disease : JAD | 23 |
| Neuron | 23 |
| Alzheimer s & Dementia | 21 |
| International journal of molecular sciences | 18 |
Studies by year published
| Year | Studies | Bar |
|---|---|---|
| 2026 | 102 | |
| 2025 | 160 | |
| 2024 | 48 | |
| 2023 | 54 | |
| 2022 | 63 | |
| 2021 | 87 | |
| 2020 | 85 | |
| 2019 | 74 | |
| 2018 | 64 | |
| 2017 | 72 | |
| 2016 | 54 | |
| 2015 | 49 | |
| 2014 | 37 | |
| 2013 | 33 | |
| 2012 | 30 | |
| 2011 | 33 | |
| 2010 | 41 | |
| 2009 | 32 | |
| 2008 | 30 | |
| 2007 | 16 | |
| 2006 | 30 | |
| 2005 | 26 | |
| 2004 | 22 | |
| 2003 | 15 | |
| 2002 | 14 | |
| 2001 | 14 | |
| 2000 | 10 | |
| 1999 | 20 | |
| 1998 | 8 | |
| 1997 | 9 | |
| 1996 | 11 | |
| 1995 | 7 | |
| 1994 | 7 | |
| 1993 | 2 | |
| 1992 | 4 | |
| 1991 | 3 | |
| 1990 | 2 | |
| 1989 | 3 | |
| 1988 | 1 | |
| 1987 | 2 | |
| 1986 | 3 | |
| 1984 | 1 | |
| 1983 | 2 |
Counts the 1,380 studies with a usable publication date. The library is a large sample of published work, not a complete index, so these counts describe the library, not the whole field.
Other subjects in the library
- Getting a diagnosis
- Biomarkers
- Clinical trials
- Prevention and risk
- Caregiving
- How common it is
- Costs and economics
- Genetics
- Laboratory science
- Vascular contributions
- Prevention trials
- Clinical safety
- Health systems and care delivery
- End-of-life care
- Risk factors
- Digital health tools
- Treatments
- Disparities
- Mild cognitive impairment
- Risk genes beyond APOE
- Brain scans and imaging
- TREM2 and immune genetics
- Cognitive tests and assessment
- Lewy body dementia
- Down syndrome and Alzheimer's
- Long-term cohort studies
- Inflammation and the immune system
- Tau biomarkers
- Brain tissue and pathology
- Drug development
- Hippocampus size on brain scans